Clinical Trials
-
Sean Gallup via Getty Images
BioNTech says dual-acting lung cancer drug helped shrink tumors
The Bristol Myers-partnered bispecific antibody kept small cell lung cancer under control in participants enrolled in a Phase 2 trial.
By Jonathan Gardner • Sept. 8, 2025 -
Dragos Condrea via Getty Images
Brain drug revivalA new class of sleep drugs draws Wall Street’s attention
Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.
By Jacob Bell • Sept. 8, 2025 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Jens Schlueter via Getty Images
VaccinesPfizer, BioNTech showcase new data supporting COVID booster
The companies said their updated shot spurred an increase in neutralizing antibodies against currently circulating strains, answering calls for more corroborating evidence.
By Delilah Alvarado • Sept. 8, 2025 -
Mohammed Haneefa Nizamudeen via Getty Images
New Summit data clouds approval pathway in lung cancer
A combination of ivonescimab and chemo didn’t extend survival over chemo alone in a global trial, missing a key goal often emphasized by regulators.
By Jonathan Gardner • Sept. 8, 2025 -
nopparit via Getty Images
Brain drug revivalRapport shares double on better-than-expected seizure drug data
One analysts called the Phase 2 study results a “best-case scenario” for a drug Rapport is developing to treat focal onset seizures.
By Ned Pagliarulo • Sept. 8, 2025 -
Dacharlie via Getty Images
Sponsored by IQVIA TechnologiesHow sponsors are staying ahead in the obesity trial landscape
Aligning digital innovation with thoughtful design is accelerating progress.
Sept. 8, 2025 -
Ignatiev via Getty Images
Sponsored by PfizerHarnessing the power of AI to detect ATTR-CM
From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.
Sept. 8, 2025 -
JHVE Photo via Getty Images
Sanofi’s touted eczema drug hits study goal, but data fall short of expectations
Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug class once viewed as particularly promising.
By Kristin Jensen • Sept. 4, 2025 -
Christoph Burgstedt via Getty Images
Wave shares sink on new study results for RNA editing drug
Updated findings from Wave’s pioneering trial continued to show its RNA editing therapy is working as intended, but wasn’t as effective in testing as investors had hoped.
By Ben Fidler • Sept. 3, 2025 -
Courtesy of Ionis Pharmaceuticals
Ionis looks to expand use of lipid-lowering drug after trial hits goal
Tryngolza, the first wholly owned drug Ionis has launched, helped people with high triglyceride levels that aren’t genetically driven.
By Jonathan Gardner • Sept. 2, 2025 -
Scott Olson via Getty Images
Lilly says breast cancer drug extended survival in study
Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard hormone therapy.
By Delilah Alvarado • Aug. 27, 2025 -
Scott Olson via Getty Images
Obesity drugs
Lilly to submit obesity pill after hitting goal in third late-stage trial
In people with diabetes and obesity, orforglipron led to weight loss near what people without diabetes experienced in prior testing.
By Jonathan Gardner • Aug. 26, 2025 -
Courtesy of Regeneron Pharmaceuticals
RNA drug from Regeneron, Alnylam succeeds in rare autoimmune disease trial
Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn't appear as effective.
By Ned Pagliarulo • Updated Aug. 26, 2025 -
Alioui Mohammed Elamine via Getty Images
Obesity drugsViking shares sink as obesity pill misses expectations in key study
The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations among people receiving Viking’s drug.
By Jonathan Gardner • Aug. 19, 2025 -
Alamy
Reunion’s psychedelic drug headed to late-stage testing
The drug, which functions similar to psilocybin, scored positive enough results in a mid-stage study that Reunion is now setting up a larger experiment to hopefully secure approval in postpartum depression.
By Jacob Bell • Aug. 18, 2025 -
Love Employee via Getty Images
Vor says drug licensed from RemeGen succeeded in Sjögren’s study
While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune condition.
By Ned Pagliarulo • Aug. 13, 2025 -
magicmine via Getty Images
Pfizer looks to expand ADC use after positive bladder cancer data
Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify for chemotherapy.
By Jonathan Gardner • Aug. 12, 2025 -
Meletios Verras via Getty Images
IO Biotech sees path forward for skin cancer vaccine despite study setback
A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe it still could win U.S. approval.
By Jonathan Gardner • Aug. 11, 2025 -
Sedat Suna via Getty Images
Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease
The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a multibillion-dollar deal that hadn’t yet paid dividends.
By Ben Fidler • Aug. 11, 2025 -
Scott Olson via Getty Images
Obesity drugsLilly shares fall as obesity pill misses expectations in key trial
While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts anticipated, leading to a selloff in shares that erased about $100 billion in market value.
By Jonathan Gardner • Aug. 7, 2025 -
Courtesy of Vertex Pharmaceuticals
Pain drugsVertex plan to build on pain drug breakthrough hits hurdles
The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain would take more testing. A successor medicine, meanwhile, fell short in Phase 2.
By Ned Pagliarulo • Aug. 5, 2025 -
Алексей Белозерский via Getty Images
A brain biotech slumps even with ‘best case’ seizure data
Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines and its experimental drug for epilepsy.
By Jacob Bell • Aug. 4, 2025 -
Scott Olson via Getty Images
Lilly’s Mounjaro protects heart health in large diabetic study
The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.
By Ned Pagliarulo • July 31, 2025 -
Douglas Olivares via Getty Images
Celcuity shares triple on late-stage results for breast cancer therapy
Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to soon file for approval.
By Delilah Alvarado • July 28, 2025 -
Eoneren via Getty Images
Atai backs away from schizophrenia drug after trial failure
The company plans to direct resources away from a drug developed by subsidiary Recognify Life Sciences and toward Atai’s wholly owned, psychedelics-focused pipeline.
By Jacob Bell • July 28, 2025
